Overview
Recognise pathological cortisol excess, distinguish exogenous exposure from endogenous Cushing syndrome, localise ACTH dependence and manage its urgent cardiovascular, metabolic, infectious and thrombotic risks.
Endogenous Cushing syndrome arises from ACTH-dependent or ACTH-independent cortisol production. Pituitary Cushing disease is the common ACTH-dependent source, but an ectopic neuroendocrine tumour may secrete ACTH. An adrenal adenoma, carcinoma or bilateral nodular disease can produce cortisol autonomously and suppress ACTH. Exogenous steroids mimic many clinical features while suppressing endogenous production.
Normal cortisol secretion has a circadian nadir around midnight and is suppressible by dexamethasone. Screening tests exploit loss of this rhythm, loss of feedback or increased integrated secretion. No single test is perfect: at least two concordant abnormal assessments are often needed, and cyclic disease may require repeated testing during symptomatic phases.
Cortisol excess causes multisystem harm even before localisation is complete. Assess blood pressure, potassium, glucose, infection, bone, mood and thrombosis throughout the diagnostic process. Severe presentations warrant accelerated specialist care because mortality is driven by cardiovascular and infectious complications, not merely the tumour mass.
Key points
- Cushing syndrome means clinically important glucocorticoid excess from any cause; Cushing disease is specifically an ACTH-secreting pituitary corticotroph tumour.
Aetiology
Exogenous glucocorticoid exposure
Systemic exposure from oral, injected, inhaled or topical glucocorticoids can reproduce cortisol effects while suppressing endogenous ACTH and adrenal function.
ACTH-dependent cortisol excess
A pituitary corticotroph adenoma causes Cushing disease, while an ectopic neuroendocrine tumour can also drive both adrenal glands through inappropriate ACTH secretion.
ACTH-independent adrenal secretion
An adrenal adenoma, carcinoma or bilateral nodular disease can produce cortisol autonomously and suppress pituitary ACTH through negative feedback.
Pathophysiology
- 1Cortisol regulation is lost
Autonomous steroid exposure removes the normal circadian nadir, feedback suppression or both, creating sustained tissue glucocorticoid activity.
- 2Protein and metabolic tissues are altered
Cortisol promotes insulin resistance, protein catabolism and fat redistribution, producing diabetes, proximal weakness, fragile skin and characteristic body-composition change.
- 3Vascular and immune harm develops
Mineralocorticoid effects, vascular sensitisation, impaired immunity and prothrombotic change contribute to hypertension, hypokalaemia, serious infection and thrombosis.
Clinical features and red flags
Proximal thigh or shoulder weakness, fragile skin, spontaneous bruising, wide purple striae, poor wound healing and osteoporosis reflect protein and connective-tissue catabolism and are more discriminating than obesity alone.
New resistant hypertension, diabetes, hypokalaemia, dyslipidaemia and central fat redistribution can signal cortisol excess, particularly when severe for age or evolving quickly.
Hyperpigmentation and androgen excess can accompany high ACTH, especially ectopic secretion or aggressive pituitary disease. Adrenal androgen excess with a large irregular mass raises concern for adrenocortical carcinoma.
Insomnia, depression, emotional lability, cognitive change or psychosis may coexist with opportunistic or muted infection. Severe behavioural change or sepsis requires urgent treatment while the endocrine diagnosis proceeds.
Cushingoid appearance during glucocorticoid therapy can coexist with suppressed adrenal reserve. Abrupt withdrawal is dangerous even though the patient appears cortisol-exposed, so taper and stress cover require planning.
Investigations
- 01
Complete glucocorticoid and medicine historyFirst step - Why
- Exclude exogenous exposure and identify drugs that invalidate biochemical tests.
- Interpretation and limitations
- Include prescribed and non-prescribed products, joint or epidural injections and potent topical therapy. Enzyme inducers can lower dexamethasone exposure, while oral oestrogen raises cortisol-binding globulin and total serum cortisol.
- 02
One-milligram overnight dexamethasone suppression test - Why
- Screen whether feedback appropriately suppresses morning serum cortisol.
- Interpretation and limitations
- Use the local timed protocol and cut-off. Non-suppression is not synonymous with Cushing syndrome; check dose timing, interacting medicines, oestrogen and physiological stress before confirmation.
- 03
Late-night salivary cortisol on repeated samples - Why
- Detect loss of the normal nocturnal cortisol nadir in an outpatient setting.
- Interpretation and limitations
- Collect at the specified clock or sleep-related time without blood, food or contamination. Shift work, disturbed sleep and acute stress can undermine interpretation; repeated abnormal values are more persuasive.
- 04
Twenty-four-hour urinary free cortisol on repeated collections - Why
- Estimate integrated unbound cortisol secretion across a full day.
- Interpretation and limitations
Differential diagnosis
Simple obesity or metabolic syndrome
Common weight gain and diabetes lack the more discriminatory combination of progressive proximal weakness, easy bruising, wide purple striae and fragility fracture.
Physiological hypercortisolism
Alcohol excess, depression, severe stress or acute illness can disturb screening tests; repeated, complementary testing in a stable context helps avoid false localisation.
Exogenous steroid effects
A complete medicine history may reveal the cause even when serum cortisol is low, distinguishing iatrogenic Cushing features from endogenous hormone production.
Management
01Case findingTest the phenotype, not obesity aloneFirst stepMultiple progressive discriminating features, unusual osteoporosis or hypertension, adrenal incidentaloma, or childhood growth failure with weight gain.+
- 1Take a comprehensive steroid and medicine history, document objective features and identify acute infection, thrombosis, glucose or blood-pressure complications needing parallel treatment.
- 2First lineChoose an appropriate first-line screen with endocrinology or the Society for Endocrinology pre-referral pathway, accounting for shift work, oestrogen, renal function and interacting medicines.
- 3Repeat or confirm abnormal results rather than ordering immediate imaging; refer urgently when clinical severity is high even if the biochemical series is still being completed.
02LocalisationACTH before anatomyEndogenous hypercortisolism confirmed by concordant specialist-interpreted testing.+
Complications
Cardiometabolic disease
Hypertension, diabetes, dyslipidaemia and vascular injury substantially increase cardiovascular risk and may require active treatment before definitive endocrine control.
Infection and thrombosis
Cortisol excess impairs immune responses and promotes clotting, making severe infection and venous thromboembolism important causes of acute deterioration.
Bone and muscle disability
Protein catabolism and altered bone turnover cause proximal weakness, osteoporosis and vertebral fractures, with functional recovery often lagging behind biochemical improvement.
Monitoring and follow-up
- Track the chosen biochemical control marker using the same assay and protocol, alongside clinical change; normalising one value does not immediately reverse cardiovascular or thrombotic risk.
- Monitor blood pressure, potassium, glucose, weight and oedema frequently during active disease and steroidogenesis inhibition, adjusting comorbidity treatment as cortisol falls.
- Screen and treat infection promptly, assess venous thromboembolism risk around active disease and surgery, and provide bone protection based on fracture assessment and local guidance.
- During cortisol-lowering medicine, teach symptoms of adrenal insufficiency and provide an emergency pathway; check liver tests or ECG specifically when the chosen agent requires them.
- After pituitary or adrenal surgery, assess remission and adrenal reserve under the endocrine protocol, manage replacement, and continue long-term surveillance for recurrence and persistent comorbidity.
Special situations
Disease is a pituitary word
Cushing disease is not interchangeable with Cushing syndrome. Using the specific term before ACTH localisation can prematurely close the diagnostic pathway.
Catabolism is discriminating
Proximal weakness, broad violaceous striae, spontaneous bruising and unexplained fractures carry more diagnostic weight than common obesity, acne or hypertension in isolation.
An incidentaloma is not a source
Small pituitary and adrenal lesions occur in people without endocrine disease. Biochemical confirmation and ACTH physiology protect patients from surgery on the wrong organ.
Cyclic disease needs timing
Symptoms and cortisol production may fluctuate. Repeating late-night saliva or urinary cortisol during an active phase can be more informative than escalating imaging after a normal quiet-phase test.
Cure creates temporary deficiency
The contralateral adrenal or remaining pituitary-adrenal axis is suppressed after successful treatment. Postoperative glucocorticoid replacement and later recovery testing are expected parts of cure.
Common pitfalls
- 01
Screening every patient with uncomplicated obesity and generating false-positive dexamethasone tests.
- 02
Failing to ask about injected, inhaled, topical or non-prescribed glucocorticoids.
- 03
Ordering pituitary MRI before proving hypercortisolism and checking ACTH dependence.
- 04
Diagnosing endogenous Cushing syndrome from one abnormal screen during acute illness or major depression.
- 05
Treating the tumour while overlooking infection, thrombosis, hypokalaemia, diabetes, fracture and psychiatric risk.
- 06
Lowering cortisol rapidly without monitoring for adrenal insufficiency or supplying emergency instructions.